Pharmaceuticals

Growth In The Orally Disintegrating Tablet Market Is Being Driven By Rising Lifestyle Disease Cases Fueling The Growth Of The Due To Increasing Demand For Preventive Health Solutions

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Orally Disintegrating Tablet Market In 2026, And How Will Its Value Evolve By 2030?

The orally disintegrating tablet market size has experienced substantial growth in recent years. It is projected to increase from $16.2 billion in 2025 to $17.62 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. Historically, this growth can be attributed to factors such as limited awareness of orally disintegrating tablets, the dominance of conventional tablets, insufficient targeting of pediatric and geriatric populations, heavy reliance on hospital pharmacy channels, and the gradual adoption of specialty drug formulations.

The orally disintegrating tablet market is projected to experience substantial expansion in the coming years, with its valuation anticipated to reach $24.43 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.5%. This expansion during the forecast period is primarily driven by various factors, including advancements in orally disintegrating tablet (ODT) formulation technology, a growing patient preference for convenient and compliant medication options, the expansion of online and retail pharmacy networks, an increasing incidence of CNS and gastrointestinal disorders, and enhanced research and development efforts in anti-psychotics and anti-epileptics. Key developments shaping the market outlook encompass a heightened demand for user-friendly and easy-to-swallow dosage forms, a broadened focus on pediatric and geriatric patient segments, the expansion of distribution channels through hospitals and retail pharmacies, an increased emphasis on therapeutics with rapid onset of action, and the growing incorporation of specialty drug classes into orally disintegrating tablet formulations.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp

Which Major Drivers Are Influencing The Expansion Of The Orally Disintegrating Tablet Market?

The increasing prevalence of neurological disorders is anticipated to stimulate the future growth of the orally disintegrating tablet market. Neurological disorders are medical conditions that impact the nervous system, encompassing the brain and peripheral nerves, thereby disrupting its normal functioning. The rise in these disorders primarily results from increased human longevity, as conditions such as Alzheimer’s and Parkinson’s become more prevalent with age, leading to an overall increase in cases. Orally disintegrating tablets offer advantages in treating neurological disorders by enabling easier and faster medication administration, especially for patients experiencing difficulty swallowing (dysphagia) or cognitive impairments. This approach enhances treatment adherence, ensures timely dosing, and boosts the overall effectiveness of therapy. For instance, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that in 2023, about 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, with projections indicating an increase to 13.8 million by 2060. Therefore, the expanding incidence of neurological disorders is a significant factor driving the growth of the orally disintegrating tablet market.

What Are The Key Segment Divisions In The Orally Disintegrating Tablet Market Segment Structure?

The orally disintegrating tablet market covered in this report is segmented –

1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes

2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores

4) By Consumer Type: Pediatric, Adult, Geriatric

Subsegments:

1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics

2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics

3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants

4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics

5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs

6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives

7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs

8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids

9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole

10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes

Which Trends Are Contributing To Changes In The Orally Disintegrating Tablet Market?

Companies operating within the orally disintegrating tablet market are prioritizing advancements in drug formulation, particularly through patient-centric drug delivery systems, to enhance treatment adherence and improve patient outcomes. A patient-centric drug delivery system involves designing and delivering medicines in a way that makes them more convenient and comfortable for patients to take, thereby enhancing their treatment experience and compliance. For example, in May 2025, Viatris Inc., a US-based healthcare company, launched Gen-Clozapine orally disintegrating tablets (ODT) in Canada, offering a new treatment option for treatment-resistant schizophrenia. This product features several distinct characteristics, establishing it as a significant addition to the management of treatment-resistant schizophrenia in Canada. Being the first clozapine orally disintegrating tablet (ODT) available in the country, it presents a patient-friendly alternative that rapidly dissolves in the mouth without water, beneficial for those with swallowing difficulties or adherence issues. The product comes in multiple strengths—12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg—allowing for flexible and precise dose adjustments based on individual patient needs. By utilizing clozapine, the only approved antipsychotic for treatment-resistant schizophrenia, the ODT formulation aligns with established treatment protocols.

Which Organizations Are Engaged In The Orally Disintegrating Tablet Market?

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

Get The Full Orally Disintegrating Tablet Market Report:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Which Region Is The Largest In The Orally Disintegrating Tablet Market?

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Orally Disintegrating Tablet Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report

Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2026, By The Business Research Company

Tablets Market Report 2026

https://www.thebusinessresearchcompany.com/report/tablets-global-market-report

Effervescent Tablet Market Report 2026

https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report

Oral Solid Dosage Pharmaceutical Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-solid-dosage-pharmaceutical-formulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795